Due to children's lower oxygen reserves and higher oxygen consumption, sedation can easily lead to respiratory adverse events such as hypoxemia. It has been reported that the incidence of hypoxemia during pediatric bronchoscopy is high, highlighting that hypoxemia in pediatric painless bronchoscopy is an urgent problem requiring a solution. High-flow nasal cannula (HFNC) oxygen therapy delivers heated and humidified breathing gas with a precisely controllable oxygen concentration, at flow rates exceeding the patient's peak inspiratory flow, directly via unsealed nasal prongs. It is a simple, comfortable, effective, and non-invasive respiratory support method that has been widely adopted in clinical practice. However, the effectiveness of HFNC in pediatric sedation remains unclear. Therefore, this multicenter randomized controlled trial aims to evaluate whether HFNC can effectively reduce the occurrence of hypoxemia during sedated bronchoscopy in pediatric patients.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
SINGLE
Enrollment
430
Using High-flow nasal cannula oxygenation
Using regular nasal cannula for oxygenation
Children's Hospital, Zhejiang University School of Medicine
Hangzhou, Zhejiang, China
The First Affiliated Hospital, Zhejiang University School of Medicine
Hangzhou, Zhejiang, China
The Second Affiliated Hospital of Wenzhou Medical University
Wenzhou, Zhejiang, China
Children's Hospital of Chongqing Medical University
Chongqing, China
The incidence of hypoxemia
75% ≤ SpO2 \< 90% for \<60 s
Time frame: Patients will be followed for the duration of hospital stay, an expected average about 2 hours
The incidence of sub-clinical respiratory depression
90% ≤ SpO2 \< 95%
Time frame: Patients will be followed for the duration of hospital stay, an expected average about 2 hours
The incidence of severe hypoxia
SpO2 \< 75% or 75% ≤ SpO2 \< 90% for ≥60 s
Time frame: Patients will be followed for the duration of hospital stay, an expected average about 2 hours
Incidence of Other Adverse Events (Excluding Respiratory-Related)
Other adverse events recorded by tools proposed by the World Society of Intravenous Anesthesia International Sedation Task Force
Time frame: Patients will be followed for the duration of hospital stay, an expected average about 2 hours
Incidence of Other Respiratory-Related Adverse Events
Time frame: Patients will be followed for the duration of hospital stay, an expected average about 2 hours
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.